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Purpose. In this study, modulation of the immune response against diphtheria toxoid (DT) by various
adjuvants in transcutaneous immunization (TCI) with microneedle array pretreatment was investigated.
Methods. TCI was performed on BALB/c mice with or without microneedle array pretreatment using DT
as a model antigen co-administrated with lipopolysaccharide (LPS), Quil A, CpG oligo deoxynucleotide
(CpG) or cholera toxin (CT) as adjuvant. The immunogenicity was evaluated by measuring serum IgG
subtype titers and neutralizing antibody titers.
Results. TCI with microneedle array pretreatment resulted in a 1,000-fold increase of DT-speciﬁc serum
IgG levels as compared to TCI. The immune response was further improved by co-administration of
adjuvants, showing a progressive increase in serum IgG titers when adjuvanted with LPS, Quil A, CpG
and CT. IgG titers of the CT-adjuvanted group reached levels comparable to those obtained after DT-
alum subcutaneous injection. The IgG1/IgG2a ratio of DT-speciﬁc antibodies decreased in the following
sequence: plain DT, Quil A, CT and CpG, suggesting that the immune response was skewed towards the
Th1 direction.
Conclusions. The potency and the quality of the immune response against DT administered by
microneedle array mediated TCI can be modulated by co-administration of adjuvants.
KEY WORDS: cholera toxin; CpG; diphtheria toxoid; microneedle array; transcutaneous immunization.
INTRODUCTION
Currently, most vaccines are administrated by injection.
Costs, risks and discomforts associated with the use and abuse
of needles have boosted research on needle-free vaccinations
(1). Around 10 years ago, Glenn, G.M et al. reported for the
ﬁrst time data on transcutaneous immunization (TCI) and
showed that strong immune responses could be induced by
topically applied cholera toxin (2) .T C Ii sp a r t i c u l a r l y
attractive because of the high accessibility of the skin and
the presence of antigen-presenting cells (APCs) in the
epidermis and dermis, in particular the Langerhans cells
(LCs) and the dermal dendritic cells (DCs) (3). However, the
upper layer of the skin, the stratum corneum, acts as a barrier
for diffusion of macromolecules and therefore is a major
obstacle to dermal vaccine delivery. To overcome this barrier
and achieve effective TCI, physical methods such as intra-
dermal injection (4,5), thermal ablation (6), microdermabra-
sion (7) electroporation (8) and cavitational ultrasound (9)
have been used. Physical disruption of the skin barrier
increases the percutanous penetration of the antigen and
makes the antigen more readily available for sampling by
APCs (10). Moreover, disruption of the skin barrier may
induce a chain of molecular events that lead to the secretion
of pro-inﬂammatory cytokines and facilitate APC activation.
A relatively novel approach to disrupt the skin barrier in a
controlled manner with little pain sensation is the use of
microneedle arrays. It was proposed ﬁrst by Gerstel and Place
already in the 1970s (11). Ten years ago, when the technology
for fabrication in micron dimensions became readily available,
Prausnitz resumed the study using microneedle arrays in
transdermal drug delivery (12). When used as a pretreatment,
microneedle arrays enable antigens to diffuse along the
transiently formed tiny conduits through the stratum corneum.
Thereby antigens may be able to approach the LCs in the
epidermis and the DCs in the dermis (13). Using ovalbumin-
coated microneedle array, Matriano et al. evaluated the
uniformity of skin piercing, and studied the dose of the vaccine
used and the kinetics and magnitude of antibody titers induced
in hairless guinea pigs (14). Widera et al.i n v e s t i g a t e dt h e
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densityofthemicroneedles,areaandcoatingofthemicroneedle
arrays, on vaccination efﬁciency of TCI (15). Hooper et al.
reportedthatsmallpoxDNAvaccine-coatedmicroneedlearrays
applied topically in combination with electroporation protected
mice against lethal challenge (16). Recently, Van Damme et al.
tested the injectable microneedle array in human volunteers
using inﬂuenza vaccine, resulting in a comparable seroprotec-
tion rate as compared to i.m. injection with 5 fold dose sparing
(17). These interesting results show that TCI using microneedle
array is promising. However, after more than 10 years of
extensive research (18,19), there continues to be a need for
further improvement of microneedle array mediated TCI, e.g.
by using potent adjuvants or novel ways of applying the
microneedle arrays.
Recently a new electric applicator was developed in our
lab. It is designed to insert microneedle arrays into the skin with
a predetermined velocity and thereby counteracts the elasticity
of the skin. This applicator enables us to reproducibly pierce
human and mouse skin in vivo with microneedles with a length
of 300 μmo rl e s s( 20). DT was recruited as a model antigen to
evaluate the potential of microneedle array pretreatment in
TCI.Inapreviousstudytheimmunogenicityoftopicallyapplied
DT was dramatically improved by microneedle array pretreat-
ment as compared to untreated skin (21).
The objective of the present study was to determine the
effect of adjuvants on the quantity and quality of the immune
response against DTafter TCI with microneedle array pretreat-
ment (M-TCI). The Th1/Th2 balance of the immune response
depends on several factors including the nature of the antigen
and the adjuvant, the delivery route and the targeted APCs, as
suggested by the ratio of IgG1/IgG2a antibody titers (22). The
adjuvants included in this study, cholera toxin (CT), lipopoly-
saccharide (LPS), synthetic oligo deoxynucleotide containing a
CpG motif (CpG), immunostimulatory fractions extracted from
the bark of the tree Quillaja saponica (Quil A) and aluminum
phosphate(alum),differintheiradjuvantmechanismandability
to modulate the immune response (see Table I)( 22). Immune
modulation by these adjuvants was evaluated in (M-)TCI and
compared withconventionalsubcutaneous(s.c.) injection of DT
or DT-alum, by measuring serum IgG (subtype) titers and
neutralizing antibody titers.
MATERIALS AND METHODS
Materials
Diphtheria toxin (batch 79/1), diphtheria toxoid (batch
98/40, protein content 12.6 mg/ml by BCA assay, 1 μg equal
to approximately 0.3 Lf) and the lpxL1 LPS were provided by
the Netherlands Vaccine Institute (NVI, Bilthoven, The
Netherlands). Horseradish peroxidase-conjugated goat anti-
mouse (HRP-GAM) IgG (γ-chain speciﬁc), IgG1 (γ1-chain
speciﬁc) and IgG2a (γ2a-chain speciﬁc) were purchased from
Southern Biotech (Birmingham, USA). Quil A and Adju-
Phos® (alum) were obtained from Brenntag Biosector
(Copenhagen, Denmark). CpG oligo deoxynucleotide 1826
(5′-tcc atg acg ttc ctg acg tt-3′, phosphorothioated) was
synthesized by Isogen Biosolutions (IJsselstein, The Nether-
lands). Chromogen 3, 3′,5 ,5 ′-tetramethylbenzidine (TMB)
and the substrate buffer were purchased from Biosource B.V.
(Nivelles, Belgium). Cholera toxin was ordered from Sigma-
Aldrich (Zwijndrecht, The Netherlands). Nimatek® (100 mg/
ml Ketamine, Euovet Animal Health B.V., Bladel, The
Netherlands), Rompun® (20 mg/ml Xylasine, Bayer B.V.,
Mijdrecht, The Netherlands) and the injection ﬂuid (0.9%
NaCl) were obtained from a local pharmacy. All other
chemicals used were of analytical grade and all solutions
were prepared with distilled water.
Animals
Female BALB/c mice (H2d), 8-week old at the start of the
experiment were purchased from Charles River (Maastricht,
The Netherlands), and maintained under standardized condi-
tions in the animal facility of the Leiden/Amsterdam Center for
Drug Research, Leiden University. The study was conducted in
conformity with the Public Health Service Policy on use of
laboratory animals and had been approved by the Research
Ethical Committee of Leiden University (UDEC, nr. 07016).
Methods
Microneedle Array and Applicator
Assembled microneedle arrays were manufactured from
commercially available 30G hypodermic needles (BD,
Alphen a/d Rijn, The Netherlands) as described previously
(13). The needles were assembled as a 300 μm-long, 4×4
array on a polymer back plate with a surface area of about
0.5 cm
2. The electric applicator was developed and optimized
as reported previously (21). The microneedles were pierced
into mouse skin using a velocity of 3 m/s.
Immunization Study
The DT-alum formulations were prepared as previously
described and the adsorption of DT to alum was between
Table I. Properties of the Adjuvants Employed in the Current Study (Adapted from (22,47,48))
Adjuvant Type Cell-mediated immunity (Th1) Humoral immunity (Th2) Receptor
Cholera toxin Exotoxin +
a +++ GM1 ganglioside
lpxL1 LPS Endotoxin ++ ++ TLR4
Quil A Saponin based +++ ++ Not identiﬁed
CpG Bacterial DNA ++++ + TLR9
Alum Inorganic salt + +++ Not identiﬁed
aHumoral and cellular immunity in arbitrary units represent the ability of adjuvants to enhance Th2 response or CTL or Th1, respectively, to
foreign antigens
1636 Ding et al.70% and 80% (23). As control groups, 5 μgo fD T( ∼1.5 Lf)
with and without alum in 100 μl solution/suspension was
administered per mouse by s.c injection. The other vaccine-
adjuvant formulations were freshly prepared by mixing DT
and the adjuvants in buffer solution in appropriate amounts
as indicated in Table II. One hundred micrograms DT and
adjuvants per mouse were applied on intact skin (TCI) or on
microneedle array pretreated skin (M-TCI) as previously
described (21,24) .Am u t a n to fL P S ,lpxL1 LPS, with
reduced toxicity but retained adjuvanticity, was employed in
this study (25). The dose of alum and lpxL1 LPS used in M-TCI
were based on the w/w ratio of antigen/adjuvant used in
injection control group and previous immunization study (25),
respectively.
During vaccination, mice were anaesthetized by intra-
peritoneal injection of 150 mg/kg ketamine and 10 mg/kg
xylazine. For all groups receiving transcutaneous vaccination,
the abdominal skin of the mice, shaved 24 h prior to
vaccination, was ﬁrst wiped with 70% ethanol. For M-TCI
group, a skin fold was supported by styrofoam and pierced
using the microneedle array and the electric applicator. Then
70 μl DT-adjuvant formulation was carefully spread to wet
the entire skin area of application (microneedle array-pre-
treated or untreated, ∼2c m
2 area restricted by a metal ring).
After 1 h of occlusive incubation, the skin area was
extensively washed with lukewarm tap water and patted dry
twice. All mice were immunized three times on day 1, 21 and
42 (at approximately the same skin region for all the TCI
groups) and sacriﬁced on day 56. Blood was sampled from the
tail vein one day before each immunization and the whole
blood was collected from the femoral artery during sacriﬁce.
Cell free sera were obtained using MiniCollect
® tubes
(Greiner bio-one, Alphen a/d Rijn, The Netherlands) by
centrifugation after clot formation and stored at −80°C.
Serum Antibody Assay
Serum IgG, IgG1 and IgG2a titers were determined by
sandwich ELISA as previously described (26). Brieﬂy,
ELISA plate (Microlon®, Greiner Bio-one, Alphen a/d Rijn,
The Netherlands) wells were coated with DT at 4°C
overnight. Two-fold serial dilutions of serum samples were
applied in the plates and the containing DT-speciﬁc anti-
bodies were detected by HRP-GAM IgG, IgG1 or IgG2a
using TMB as substrate. Antibody titers are expressed as the
reciprocal of the calculated sample dilution corresponding to
half of the maximum absorbance at 450 nm of a complete s-
shaped absorbance-log dilution curve. If samples were not
diluted in the optimal range, additional measurements were
performed to generate an s-shaped curve. Subsequently, the
titers were calculated using a four-parameter ﬁtting of the
curve. Samples that did not reach the half-saturated absor-
bance value at the lowest (ten fold) dilution were considered
as non-responders.
Neutralizing Antibody Assay
Immunity against diphtheria depends on the presence of
circulating toxin-neutralizing antibodies. These antibodies were
evaluated using Vero cell test, the WHO standard method to
assess the success of diphtheria vaccination, which relies on the
inhibition of a cytotoxic dose of diphtheria toxin (26). In brief,
aftercomplementinactivation,two-foldserialdilutionsofserum
samples were prepared with complete medium 199 (CM199,
Gibco,Breda,TheNetherlands)andappliedtomicrotiterplates
(CELLSTAR®,GreinerBio-one,Alphena/dRijn,TheNether-
lands). Subsequently, 2.5×10
−5 Lf diphtheria toxin was added to
the wells. After 2 h incubation at 37°C for neutralization, Vero
cellssuspensioninCM199wasaddedtoeachwell.Coveredwith
a plate sealer, Vero cells were incubated at 37°C in 5% CO2 for
6 days. The end point was taken as the highest serum dilution
protecting the Vero cells.
Statistical Analysis
ELISA titers were logarithmically transformed for better
normality before statistical analysis. Two way ANOVA with
Bonferroni posttest, one way ANOVAwith Tukey posttest, or
Kruskal–Wallis nonparametric test with Dunns posttest were
performed as indicated. Statistical analysis was carried out
using Prism Graphpad and a p value less than 0.05 was
considered to be signiﬁcant.
RESULTS
During the immunization study, there was no adverse
effect from the shaving, anesthesia, piercing, immunization, or
washing procedure observed. Neither erythema nor indura-
Table II. Formulations Prepared for In Vivo (M-)TCI Study
DT dose (μg) Adjuvants Adjuvant dose (μg) Solvent (pH) Volume (μl)
for s.c. injection
5 AlPO4 150 0.9% saline (7.0) 100
5 –– 0.9% saline (7.0) 100
(M)-TCI
100 –– PBS
a (7.4) 70
100 lpxL1 LPS 25 PBS/Tris
b (7.4) 70
100 Quil A 100 PBS (7.4) 70
100 CT 100 PBS (7.4) 70
100 CpG 100 PBS (7.4) 70
100 AlPO4 3,000 0.9% saline (7.0) 70
aPBS: 2.67 mM KCl, 1.47 mM KH2PO4, 137.93 mM NaCl, 8.06 mM Na2HPO4·7H2O, without Ca
2+and Mg
2+
bPBS/Tris: PBS mixed with 1 mM Tris–HCl (v/v=5:3).
1637 Immune Modulation in Transcutaneous Immunizationtion was seen at the immunization site after exposure of
antigen and adjuvants.
Immune Response Improved by Microneedle Array
Pretreatment
The IgG titers of mice from all groups after prime, ﬁrst
boost and second boost (day 20, 41 and 56) are shown in
Fig. 1a–e and an overview of the DT-IgG titers after the
second boost is shown in Fig. 1f. It is clear that non-
adjuvanted DT did not result in a substantial IgG response
when applied on intact skin (TCI). Microneedle array
pretreatment provided major improvement to the immuno-
genicity of DT. After prime, more mice responded with
higher mean IgG titers in the M-TCI group than in the TCI
group. After the ﬁrst boost, all mice responded and the IgG
titers were 100 fold higher in the M-TCI group (p<0.01) and
the difference of IgG titers was further increased to over
1,000 fold after the second boost (p<0.001, Fig. 1a). Immu-
nogenicity of DTwas further improved by the co-administered
adjuvants e.g. Quil A, CpG and CT in M-TCI. The
improvement by the adjuvant in question is indicated by
the space in between the black and the brown lines in
Fig. 1b, c, d and e, respectively. DT-speciﬁc IgG titers in the
CT M-TCI group after the second boost were the highest
among all M-TCI groups and reached very close level to
those from DT-alum injection group (p>0.05). For the
adjuvants in the absence of microneedle array pretreatment,
their effects on the DT immunogenicity were more variable
and less pronounced. Only CT moderately improved the
IgG titers after the second boost (Fig. 1a, e, p<0.05), while
the presence of the other adjuvants did not augment the
IgG titers signiﬁcantly. Comparing the two injection control
groups, alum speeded up IgG development and increased
the IgG titers signiﬁcantly (p<0.001 after ﬁrst boost).
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Fig. 1. DT-speciﬁc IgG titers to dermally delivered DT with (M-TCI) and without (TCI) microneedle array pretreatment of
the skin: a Plain DT; b DT + LPS; c DT + Quil A; d DT + CpG; e DT + CT. Sera were collected after prime, ﬁrst boost and
second boost (day 20, 41 and 56) and antibodies were determined by ELISA. TCI with DT + LPS was not carried out. An
overview of the DT-speciﬁc IgG titers after the second boost for the M-TCI and s.c. injection groups are shown in f. Data are
shown as mean + SD (n=8). Non-responders were given an arbitrary titer of 10 (*p<0.05, **p<0.01, ***p<0.001, two way
ANOVA with Bonferroni posttest).
1638 Ding et al.However, when DT-alum was applied in M-TCI, no
adjuvanticity was observed as the IgG titers were lower
than those of plain DT in M-TCI (data not shown).
Immune Modulation by Adjuvants in M-TCI
Focusing on the M-TCI, immune modulation functions of
the adjuvants were investigated. The DT-speciﬁc IgG1 and
IgG2a titers in the sera collected after prime, ﬁrst boost and
second boost (day 21, 42 and 56) were determined (Fig. 2).
For all adjuvants, IgG1 showed similar titers as compared to
the total IgG titers and each vaccination showed a booster
effect. After the ﬁrst boost, Quil A and CT enhanced the
IgG1 titers signiﬁcantly as compared to plain DT (p<0.01 and
0.001, respectively). After the second boost, only CT signif-
icantly enhanced the IgG1 titers as compared to plain DT (p<
0.01). A clear effect of the adjuvants on the IgG2a titers was
observed after the second boost, which increased in the
following sequence: plain DT, LPS, Quil A, CT and CpG.
The IgG1/IgG2a ratio, which is considered a measure for
the Th1/Th2 balance of the immune response (27), of
individual mice from each group after the second boost was
calculated and presented in Fig. 3. Plain DT and DT-alum
induced an IgG1 biased response when delivered via s.c.
injection. Applying plain DT by M-TCI induced the same
IgG1/IgG2a ratio as by s.c. injection. With adjuvants, the ratio
decreased in the following sequence: plain DT, Quil A, CT
and CpG, suggesting that the Th2 biased immune response
induced by plain DT was skewed towards the Th1 direction.
Protective Immunity of DT in M-TCI
T h ep r o t e c t i v ei m m u n i t yof DT with the serial of
immune modulators in M-TCI was evaluated using the Vero
cells test (Fig. 4). Although for LPS, Quil A and CpG groups
the neutralizing antibody titers were not signiﬁcantly different
from those for plain DT, improvement was seen for the CT
group (p<0.05). The mean titer was very close to that of the
DT-alum injection group, and the difference was not signif-
icant (p>0.05). As expected, the groups that had received
formulations on untreated skin (TCI) did not show detectable
neutralizing antibody titers.
DISCUSSION
This is the ﬁrst study in which the immune modulatory
activity of several known adjuvants was directly compared in
TCI with microneedle array pretreatment, using DT as a
model antigen. In this study, we ﬁrst compared the immune
responses of DT formulated with different adjuvants in TCI
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Fig. 2. DT-speciﬁc IgG1 and IgG2a titers during M-TCI. Sera were collected after prime,
ﬁrst boost and second boost (day 20, 41 and 56) and antibodies were determined by
ELISA. Data shown as mean + SD (n=8). Non-responders were given an arbitrary titer of
10. (*p<0.05, **p<0.01, ***p<0.001, two way ANOVA with Bonferroni posttest).
1639 Immune Modulation in Transcutaneous Immunizationand M-TCI. Then we focused our study on the modulation
capability of these adjuvants to the immune response in M-TCI.
Application of DT on intact skin did not induce a
substantial immune response in the absence or presence of
the tested adjuvants. The poor penetration of DT across the
stratum corneum seems to be the limiting factor, since the
antibody titers of DT in TCI was strongly increased by
microneedle array pretreatment. The skin barrier disruption
and increased DT diffusion across the stratum corneum
provided remarkable improvement to the immune response
via TCI, similar as the tape-stripping method, however,
through a practically easier and more controllable approach
(28). Co-administration of adjuvants in M-TCI was able to
further augment the immunogenicity of DT and demonstrat-
ed marked differences between the immune stimulatory
activities of the adjuvants. In the following section, the tested
adjuvants are discussed individually concerning their mecha-
nism of action and the role of delivery route in the
augmentation and modulation of DT immune response.
CT is a molecule with ﬁve nontoxic B subunits (CTB)
surrounding a single, toxic A fragment (CTA). Both the CTB-
mediated speciﬁc binding to the GM1 ganglioside receptors
and the ADP-ribosyltransferase activity of CTA have been
reported to be of importance for the immune stimulatory
properties of CT (29,30). Whereas CT is a well-documented
Th2 immune modulator in conventional and mucosal vacci-
nation (30), our results point to a more Th1 biased response
against DT when co-administered with CT via M-TCI. The
Th1 skewing of CT in TCI was also reported by Stickings et
al. using mutant diphtheria toxin, CRM197, as model antigen
(31) and by Skountzou et al. using inﬂuenza vaccine (32). This
suggests that the Th1 skewing of CT is delivery-route
dependent. Studies performed by Anjuere et al. using
ovalbumin as prototype antigen clariﬁed that CTB suppresses
systemic Th1 responses when given by a mucosal route, but
potentiates these responses when administered by TCI. This
ﬁnding underscores the role of the epithelial microenviron-
ment in the regulation of immune responses and reﬂects the
DC heterogeneity between mucosal tissue and skin (33).
The signaling of CpG starts by engagement of Toll-like
receptor 9 (TLR9), followed by induction of pro-inﬂammatory
cytokine (e.g. IL-12, TNF-α and IFN-γ) expression, and results
in a Th1 biased response (34). In our present study, CpG
induced the highest IgG2a titers among all M-TCI groups and
our results strongly support a skewing of the Th1/Th2 balance
towards the Th1 direction, similar to the immune modulatory
effect of CpG in mucosal and injection vaccination. Although
at the site of application TLR9 is not constitutively expressed
by the LCs, it is almost exclusively expressed by the
keratinocytes in the upper and most differentiated layer of
the epidermis. Their TLR9 expression and reactivity to CpG is
reported to be greatly up-regulated by transforming growth
factor (TGF-α), a growth and differentiation factor present
after skin barrier disruption and during wound healing (35).
Quil A is composed of immune-stimulatory fractions
extracted from the bark of the tree Quillaja saponica.T h e
Quil A concentration (1.43 mg/ml) used in the applied
formulation was well above its reported critical micelle
concentration of 0.3 mg/ml (36). The average particle size of
the DT-Quil A dispersion in PBS was about 56 nm with a PDI
of 0.10, as measured by dynamic light scattering. Quil A is a
potent Th1 biased adjuvant when given by i.m. injection (37).
In M-TCI, it improved the IgG titers marginally as compared
to the non-adjuvanted DT (p<0.05 after the ﬁrst boost; p>0.05
after the second boost). The ratios of anti-DT IgG1/IgG2a
titers were signiﬁcantly lowered as compared to M-TCI of
plain DT (p<0.01), suggesting that it skewed the response
towards the Th1 direction.
LPS, major outer membrane constituent of Gram-
negative bacteria, stimulates APCs through TLR4, induces
high levels of pro-inﬂammatory cytokines and usually leads
to a strong Th1 response (38). The DT-lpxL1 LPS disper-
sion applied in our study had a bigger average particle size
than Quil A, about 300 nm with a PDI of 0.45, indicating
that relatively large complexes had been formed. In M-TCI,
t h ee f f e c to ft h elpxL1 LPS mutant on the anti-DT IgG,
IgG1, IgG2a and the neutralizing antibody titers was not
signiﬁcant (p>0.05). This may be due to the following
factors: (a) LCs do not express TLR4 and do not respond to
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Fig. 4. Diphtheria toxin-neutralizing antibody titers after M-TCI.
Serum samples were collected after the second boost (day 56) and
determined by Vero cell test. Data are expressed as logarithm of the
highest dilution that was still capable of protecting the Vero cells from
the challenge of diphtheria toxin (filled circle the M-TCI groups,
empty circle the injection groups, *p<0.05, **p<0.01, ***p<0.001,
Kruskal–Wallis nonparametric test with Dunns posttest).
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Fig. 3. DT-speciﬁc IgG1/IgG2a ratios of individual mouse after M-
TCI. Sera were collected on day 56, DT-speciﬁc IgG1 and IgG2a
titers were measured by sandwich ELISA. IgG1/IgG2a ratios were
calculated only using IgG2a responders. Data shown as mean + SD
(n=8, **p<0.01 and ***p<0.001, one-way ANOVA with Tukey
posttest).
1640 Ding et al.bacteria or LPS (39). TLR4 expression by mouse keratinocytes
also seems limited. Besides few data available from mice,
reports on TLR4 expression by human keratinocytes are
conﬂicting (40,41); (b) Although little is known about the actual
diffusion of these dispersions across the conduits induced by the
microneedles, previous studies of our group showed that
ﬂuorescently labeled particles of ca. 200 nm did pass through
the conduits created by the same microneedle arrays as used in
the present study (20). However, as no quantitative information
is available, it is possible that only a limited amount of the DT-
lpxL1 LPS dispersion reached the DCs in the dermis; (c) the
LPS mutant may work in a less efﬁcient way as the original LPS
in the epidermal/dermal microenvironment. Further studies are
required to elucidate the exact mechanism. The different
reactivity of skin immune system to CpG and LPS may be
involved in a strategic control of host defense to the bacterial
commensal skin ﬂora (39).
Alum did not show any adjuvanticity in M-TCI. It induced
lower IgG and IgG1 titers than those of non-adjuvanted DT
group after each vaccination. Furthermore, alum in M-TCI did
not induce detectable IgG2a titers and provided no protection
in the Vero cell test after the second boost (data not shown).
This may partially be due to the size of DT-alum particles,
several microns in diameter, which prevents their diffusion
through the conduits in sufﬁcient amount to exert a ‘depot’
effect (42). The adjuvanticity of alum could also be dependent
on the epithelial microenvironment; the danger signal it
induces through injection, the uric acid production (43), may
not be provoked in the dermis and epidermis.
Interestingly, when comparing IgG subtype titers and
neutralizing antibody titers between CpG and Quil A groups
(Figs. 1 and 4), the CpG group, with similar IgG titers, but
much higher IgG2a titers than the other, induced similar to
slightly lower neutralizing antibody titers, which indicates that
IgG2a might not contribute to toxin-neutralization. This was
conﬁrmed by the comparison between CpG and CT groups,
also showing that higher IgG2a titers did not result in higher
neutralizing antibody titers. IgG1 seems to be the main
neutralizing antibody for protection, as IgG1 titers signiﬁ-
cantly correlated with neutralizing titers. However, IgG1 titers
could not be used to predict individual neutralizing antibody
titers with great accuracy, which is in line with a diphtheria
vaccination study done in human infants (44). Therefore, from
an application perspective, CpG in M-TCI is more suitable for
anti-viral immune responses such as inﬂuenza vaccination
where IgG2a provides the main immune protection and a Th1
biased response is more desired (45).
In this study, a high dose of DT, 20 times of that used in
the s.c. injection group, was applied in M-TCI. This dose is
similar to the dose of DT used by Glenn et al. in previous
studies (24,46). High doses were used as apparently only a
fraction of DT applied actually enters epidermis/dermis. A
limiting factor for diffusion of the antigen into the skin is that
the mice used for this study can only be kept under anesthesia
for about 1 h. This is not a limitation of the transcutaneous
route, but a limitation of the animal model used. The high
doses used until now also indicate that formulation improve-
ment to increase the efﬁciency of the immune response is
very important in transcutaneous vaccination. Conjugation
and encapsulation of adjuvants into vaccine-containing par-
ticles and speciﬁc DC and LC targeting approaches could be
attractive strategies to further improve the potency of vaccine
formulations for M-TCI.
CONCLUSION
We have shown that the type of adjuvant used has a
signiﬁcant effect on the immune response and protective
immunity against DT in M-TCI. The epithelial microenviron-
ment and DC heterogeneity also play an important role in the
regulation of the immune response. This delivery method is
applicable to many other vaccines by formulating with proper
adjuvants and holds a lot of promise for future use.
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